Konakion

Phytomenadione, the active ingredient in Konakion, is a Vitamin K (phytonadione) presented as a unknown/unknown for intravenous and oral use. It treats vitamin K deficiency bleeding, reverses over‑anticoagulation from oral anticoagulants, and provides prophylaxis of hemorrhage in newborns. GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konakion acts on the coagulation pathway to correct vitamin K‑dependent clotting factor deficiencies. - Vitamin K deficiency bleeding: restores functional clotting factors to prevent or treat bleeding episodes. - Newborn hemorrhage prophylaxis: provides essential vitamin K to newborns to reduce risk of early bleeding. - Warfarin reversal: rapidly counteracts excessive anticoagulation caused by oral vitamin K antagonists.

Adverse reactions may occur following administration of Konakion.

Common Side Effects: - Injection site pain or erythema - Transient fever or chills - Nausea or mild vomiting - Headache or dizziness - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Acute hypotension leading to shock - Thromboembolic events such as deep‑vein thrombosis - Hemolysis or severe hematuria - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Konakion should be used with careful clinical assessment and monitoring. - Assess bleeding risk: evaluate coagulation status before administration. - Monitor INR: check clotting parameters after dosing to guide further therapy. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in neonates: follow specific neonatal dosing guidelines. - Pregnancy and lactation: weigh potential benefits against risks and consult a specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Konakion may interact with several anticoagulant and medication classes.

Major Interactions (Avoid): - Warfarin: antagonizes anticoagulant effect, may require dose adjustment. - Acenocoumarol: similar antagonism, can lead to loss of anticoagulation. - Broad‑spectrum antibiotics: may alter gut vitamin K synthesis, affecting response.

Moderate Interactions (Monitor Closely): - Heparin: additive anticoagulant effect, monitor coagulation parameters. - Oral contraceptives: potential increased clotting risk, observe for thrombosis. - Hepatotoxic chemotherapy agents: may modify clotting factor synthesis, requiring closer INR monitoring.